Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

August 11, 2017: By Jon Swedien

Allegro logoAllegro Ophthalmics on Aug. 9 reported positive results from its Phase IIb Stage 2 clinical trial for Luminate.

Luminate—a first-in-class integrin peptide therapy that treats neovascular retinal diseases—met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME) in the DEL MAR Stage 2 study, according to the San Juan Capistrano, California, company.

The primary endpoint was non-inferiority to bevacizumab in mean change in best-corrected visual acuity (BCVA) at 20 weeks when Luminate was used with a single bevacizumab pretreatment (sequential therapy) or in combination with bevacizumab.

The Luminate results were achieved after one treatment of 1.25 mg bevacizumab (week zero) followed by three 1 mg Luminate injections (weeks one, four, and eight) and 12 weeks off treatment, compared with five injections given every four weeks with bevacizumab.

The data showed the mean gain in BCVA was 7.1 letters for patients in the Luminate with bevacizumab pretreatment (sequential) group compared with 6.7 letters for patients in the bevacizumab control group.

The double-masked, placebo-controlled, randomized, multicenter, five-month Phase IIb, Stage 2 trial, conducted at 14 US sites, included five arms:

— Luminate 0.5 mg or 1.0 mg as a sequential therapy after a single treatment of 1.25 mg bevacizumab (week zero) followed by three Luminate injections (weeks one, four, and eight), and 12 weeks off treatment;

— Luminate 0.5 mg or 1.0 mg given in direct combination with bevacizumab 1.25 mg at weeks one, four, and eight, and 12 weeks off treatment;

— A 1.25 mg bevacizumab control arm of five monthly injections.

The trial also found that Luminate was well-tolerated with no drug toxicity or intraocular inflammation. These safety results are consistent with previously conducted Luminate studies on human subjects where there were no reports of significant inflammation and no evidence of retinal tears or detachments.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022